Pharmacokinetic and pharmacodynamic evaluation for tissue-selective inhibition of cholesterol synthesis by pravastatin

Journal of Pharmacokinetics and Biopharmaceutics

Volumn 26, Issue 3, 1998, Pages 329-347

  Hatanaka, Tomomi ^a   Honda, Shohei ^a   Sasaki, Seiji ^a   Katayama, Kazunori ^a   Koizumi, Tamotsu ^a  

^a UNIVERSITY OF TOYAMA   (Japan)

Author keywords

Cholesterol synthesis; HMG CoA reductase inhibitors; Pharmacodynamics; Pharmacokinetics; Pravastatin; Tissue selectivity

Indexed keywords

CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PRAVASTATIN;

ANIMAL EXPERIMENT; ARTICLE; BILIARY EXCRETION; CHOLESTEROL SYNTHESIS; DOSE RESPONSE; DRUG ACTIVITY; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG SCREENING; DRUG SELECTIVITY; HYPERCHOLESTEROLEMIA; INTRAVENOUS DRUG ADMINISTRATION; MALE; MODEL; NONHUMAN; PRIORITY JOURNAL; RAT; STEADY STATE;

ADMINISTRATION, ORAL; ANIMALS; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INJECTIONS, INTRAVENOUS; LIVER; MALE; NONLINEAR DYNAMICS; ORGAN SPECIFICITY; PRAVASTATIN; RATS; RATS, WISTAR;

EID: 0032456123     PISSN: 0090466X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. J. M. Hoeg and H. B. Brewer, Jr. 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors in the treatment of hypercholesterolemia. J. Am. Med. Assoc. 258:3532-3536 (1987).
2. D. R. Illingworth and J. A. Tobert. A review of clinical trials comparing HMG-CoA reductase inhibitors. Clin. Ther. 16:366-385 (1994).
3. A. T. M. Serajuddin, S. A. Ranadive, and E. M. Mahoney. Relative lipophilicities, solubilities, and structure-pharmacological consideration of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors pravastatin, lovastatin, mevastatin, and simvastatin. J. Pharm. Sci. 80:830-834 (1991).
4. T. Komai, E. Shigehara, T. Tokui, T. Koga, M. Ishigami, C. Kuroiwa, and S. Horiuchi. Carrier-mediated uptake of pravastatin by rat hepatocytes in primary culture. Biochem. Pharmacol. 43:667-670 (1992).
5. K. Ziegler and S. Hummelsiep. Hepatoselective carrier-mediated sodium-independent uptake of pravastatin and pravastatin-lactone. Biochim. Biophys. Acta 1153:23-33 (1993).
6. +-independent multispecific anion transporter mediates active transport of pravastatin into rat liver. Am. J. Physiol. 264:G36-G44 (1993).
7. Y. Tsujita, M. Kuroda, Y. Shimada, K. Tanizawa, M. Arai, I. Kaneko, M. Tanaka, H. Masuda, C. Tarumi, Y. Watanabe, and S. Fuji. CS-514, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase: Tissue-selective inhibition of sterol synthesis and hypolipidemic effect on various animal species. Biochim. Biophys. Acta 877:50-60 (1986).
8. T. Koga, Y. Shimada, M. Kuroda, Y. Tsujita, K. Hasegawa, and M. Yamazaki. Tissue-selective inhibition of cholesterol synthesis in vitro by pravastatin sodium, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Biochim. Biophys. Acta 1045:115-120 (1990).
9. T. Koga, K. Fukuda, Y. Shimada, M. Fukami, H. Koike, and Y. Tsujita. Tissue selectivity of pravastatin sodium, lovastatin and simvastatin. Eur. J. Biochem. 209:315-319 (1992).
10. A. K. van Vliet, G. C. F. van Thiel, R. H. Huisman, H. Moshage, S. H. Yap, and L. H. Cohen. Different effects of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors on sterol synthesis in various human cell types. Biochim. Biophys. Acta 1254:105-111 (1995).
11. P. K. Gupta and C. T. Hung. Quantitative evaluation of targeted drug delivery systems. Int. J. Pharm. 56:217-226 (1989).
12. G. Levy. Targeted drug delivery: Some pharmacokinetic considerations. Pharm. Res. 4:3-4 (1987).
13. A. Boddy and L. Aarons. Pharmacokinetic and pharmacodynamic aspects of site-specific drug delivery. Adv. Drug Deliv. Rev. 3:155-163 (1989).
14. J. I. Germershausen, V. M. Hunt, R. G. Bostedor, P. J. Bailey, J. D. Karkas, and A. W. Alberts. Tissue selectivity of the cholesterol-lowering agents lovastatin, simvastatin and pravastatin in rats in vivo. Biochim. Biophys. Res. Commun. 158:667-675 (1989).
15. M. Berman, E. Shahn, and M. F. Weiss. The routine fitting of kinetic data to models: A mathematical formalism for digital computers. Biophys. J. 2:275-287 (1962).
16. A. Endo, M. Kuroda, and Y. Tsujita. ML-236A, ML-236B and ML-236C, new inhibitors of cholesterogenesis produced by Penicillium citrium. J. Antibiot. 29:1346-1348 (1977).
17. A. Endo, Y. Tsujita, M. Kuroda, and K. Tanzawa. Inhibition of cholesterol synthesis in vitro and in vivo by ML-236A and ML-236B, competitive inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. Eur. J. Biochem. 77:31-36 (1977).
18. T. M. A. Bocan, E. Ferguson, W. McNally, P. D. Uhlendorf, S. B. Muller, P. Dehart, D. R. Sliskovic, B. D. Roth, B. R. Krause, and R. S. Newton. Hepatic and nonhepatic sterol synthesis and tissue distribution following administration of a liver selective HMG-CoA reductase inhibitor, CI-981: Comparison with selected HMG-CoA reductase inhibitors. Biochim. Biophys. Acta 1123:133-144 (1992).
19. T. Komai, K. Kawai, T. Tokui, Y. Tokui, C. Kuroiwa, E. Shigehara, and M. Tanaka. Disposition and metabolism of pravastatin sodium in rats, dogs and monkeys. Eur. J. Drug Metab. Pharmacokin. 17:103-113 (1992).
20. S. M. Singhvi, H. Y. Pan, R. A. Morrison, and D. A. Willard. Disposition of pravastatin sodium, a tissue-selective HMG-CoA reductase inhibitor, in healthy subjects. Br. J. Clin. Pharmacol. 29:239-243 (1990).
21. D. W. Everett, T. J. Chando, G. C. Didonato, S. M. Singhvi, H. Y. Pan, and S. H. Weinstein. Biotransformation of pravastatin sodium in human. Drug Metab. Dispos. 19:740-748 (1991).
22. J. H. Lin, Y. Sugiyama, S. Awazu, and M. Hanano. Physiological pharmacokinetics of ethoxybenzamide based on biochemical data obtained in vitro as well as on physiological data. J. Pharmacokin. Biopharm. 10:649-661 (1982).
23. A. Tsuji, H. Takanaga, I. Tamai, and T. Terasaki, Transcellular transport of benzoic acid across Caco-2 cells by a pH-dependent and carrier-mediated transport mechanism. Pharm. Res. 11:30-37 (1994).
24. K. Sasahara. Pharmacokinetics of HMG-CoA reductase inhibitors. Prog. Med. 11:2413-2427 (1991).
25. G. A. Keller, M. C. Barton, D. J. Shapiro, and S. J. Singer. 3-Hydroxy-3-methylglutaryl-coenzyme A reductase is present in peroxisome in normal rat liver cells. Proc. Natl. Acad. Sci. U.S. 82:770-774 (1985).